Resources for you and your office

CTEXLI at a Glance

Get a comprehensive look at CTEXLI—from how it works to how it’s taken and more.

Resources for your patients with CTX

CTX Alliance

The CTX Alliance is a patient organization solely dedicated to providing resources and support, and promoting CTX research for patients, families, and health care providers.

Visit the CTX Alliance

CTEXLI Patient Brochure

Provide this resource to patients who are considering or recently prescribed CTEXLI treatment.

Download Patient Brochure

Stay in the Know

Fill out this form to receive more information about CTEXLI as it becomes available.

Fill Out Form

Mirum Access Plus is available to support you, your office, and your patients

To learn more about Mirum Access Plus, contact us at 1-855-MRM-4YOU (1‑855‑676‑4968) Monday through Friday, 8:00 AM through 8:00 PM ET.
See MAP Resources

Get started with CTEXLI

Complete the Patient Enrollment Form to prescribe CTEXLI.

Prescribe Now

First and only FDA-approved treatment for CTX in adults

CTEXLI is designed to stop the overproduction of toxic bile acid precursors.¹

See How It Works

INDICATION

CTEXLI is indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Chenodiol, including CTEXLI, has been associated with hepatotoxicity. Patients with preexisting liver disease or bile duct abnormalities may be at a higher risk for hepatotoxicity during treatment.

Before initiating CTEXLI, obtain baseline liver transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and total bilirubin levels in all patients. Monitor liver transaminase (ALT, AST) and total bilirubin levels yearly and as clinically indicated. If liver transaminase levels are elevated >3 times the upper limit of normal (ULN) or total bilirubin level is >2 times ULN, interrupt treatment until the levels have returned to baseline values. For persistent or recurrent liver test abnormalities, consider discontinuing CTEXLI.

Inform the patient of the symptoms of hepatotoxicity (e.g., abdominal pain, bruising, dark-colored urine, fatigue, bleeding, jaundice, nausea, and pruritus). Have the patient discontinue CTEXLI immediately if clinical signs and symptoms consistent with hepatotoxicity occur.

ADVERSE REACTIONS

The most common adverse reactions (≥14%) during CTEXLI treatment were diarrhea, headache, abdominal pain, constipation, hypertension, muscular weakness, and upper respiratory tract infection.

DRUG INTERACTIONS

Bile acid sequestering agents and aluminum-based antacids: Avoid concomitant use with CTEXLI. Co-administration of bile acid sequestering agents, such as cholestyramine and colestipol, or aluminum-based antacids may decrease absorption of CTEXLI in the intestine and may result in decreased efficacy.

Coumarin and its derivatives: Monitor prothrombin time and adjust the dosage of coumarin or its derivatives if concomitant use with CTEXLI is unavoidable. Due to potential hepatotoxicity, CTEXLI may affect the pharmacodynamics of coumarin and its derivatives, causing unexpected prolongation of the prothrombin time and hemorrhage.

DOSING AND ADMINISTRATION

The recommended dosage of CTEXLI is 250 mg administered orally three times daily, with or without food. Swallow tablets whole.

Please see accompanying full Prescribing Information.